Cyclerion Therapeutics
CYCN
19 hedge funds and large institutions have $1.23M invested in Cyclerion Therapeutics in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
27% more funds holding
Funds holding: 15 → 19 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24.38% less ownership
Funds ownership: 38.47% → 14.1% (-24%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
54% less capital invested
Capital invested by funds: $2.7M → $1.23M (-$1.47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$29.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$26.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.79K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$362 |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$278 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
-$927K |
| 2 |
MP
MFN Partners
Boston,
Massachusetts
|
-$437K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$426K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$5.81K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$11 |
CYCN Hedge Fund Activity: Q4 2024 in Review
19 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q4 2024, worth a combined $1.23M — down 54% from $2.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CYCN positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $29.5K. The largest seller was Slate Path Capital, exiting entirely with an estimated $927K sold.
- 19 institutional investors held Cyclerion Therapeutics (CYCN) as of Q4 2024, up from 15 in Q3 2024.
- Funds reported $1.23M of Cyclerion Therapeutics stock for Q4 2024, down 54% quarter-over-quarter.
- 6 funds opened new Cyclerion Therapeutics positions in Q4 2024 and 2 closed out, a net change of +4 holders.
- The largest Cyclerion Therapeutics buyer in Q4 2024 was Renaissance Technologies, an estimated $29.5K added.
- The largest Cyclerion Therapeutics seller in Q4 2024 was Slate Path Capital, an estimated $927K sold.
Based on aggregated 13F filings for Q4 2024.